Tag:
T-DM1
Latest Headlines
Latest Headlines
Top 10 late-stage cancer drugs in 2012
Thousands of experimental meds are winding their way through various stages of clinical trials today, and the largest category among the contenders is cancer drugs.
Is ImmunoGen overvalued?
The drug delivery company may not be worth the $1.2 billion its investors would believe.
UPDATED: Roche readies for approvals of previously snubbed breast cancer drug
Roche has turned in positive data from a key Phase III study of its blockbuster hopeful T-DM1.
Roche wins landmark approval for targeted cancer drug vismodegib
Roche ( $RHHBY ) and Genentech won a landmark approval for the cancer drug vismodegib today. After gaining significant efficacy data from a Phase II study on basal cell carcinoma, the drug giant not
Roche trial buoys antibody-based delivery of cancer drugs
The antibody-drug conjugate field has had its ups and downs, but lately developers of such therapies--which use targeted antibodies attached to anti-cancer toxins to home in on tumor cells--have been
Roche's T-DM1 generates a fresh blast of positive PhII data
Roche's T-DM1 was back in the spotlight in Stockholm as well. In a mid-stage trial of 137 women with advanced breast cancer, the treatment triggered a 41% drop in the risk of disease progression when
Roche unveils more promising data on T-DM1
Roche says that it has landed a promising set of survival and safety data from a mid-stage study of its closely-watched breast cancer treatment T-DM1 . While keeping the actual data under wraps,
ImmunoGen touts new drug-delivering antibodies
After forming partnerships with several major pharmas, ImmunoGen wants to boost its pipeline of proprietary antibody-drug conjugates. The Waltham, MA-based biotech ( $IMGN ) carried this message last
Roche spotlights top late-stage drug prospects in pipeline review
What's Roche willing to bet hundreds of millions of dollars on next year? This morning the pharma giant answered that question by highlighting its 14 late-stage prospects in the pipeline, promising
Roche CEO touts 'stunning' breast, lung cancer data
Hours ahead of the 2010 European Society for Medical Oncology meeting in Milan, Roche CEO Severin Schwan ( photo ) is talking up data from two of his company's cancer drugs: T-DM1, a breast cancer
